

# Obesity and Cancer

---


*Zobeida Cruz-Monserrate Ph.D.*

*PancreasFest*

*July 2019*



# What are some environmental factors that increase the risk of developing cancer?



World  
Cancer  
Research  
Fund



American  
Institute for  
Cancer  
Research

CUP Continuous  
Update  
Project

Analysing research on cancer  
prevention and survival

## Diet, nutrition, physical activity and cancer: a global perspective

A summary of the Third Expert Report



World  
Cancer  
Research  
Fund International



World  
Cancer  
Research  
Fund UK



Wereld  
Kanker  
Onderzoek  
Fonds



World  
Cancer  
Research  
Fund

世界癌症研究基金会

## Diet, nutrition, physical activity and cancer: a global perspective

A summary of the Third Expert Report



2012	DIET, NUTRITION, PHYSICAL ACTIVITY AND PANCREATIC CANCER		
		DECREASES RISK	INCREASES RISK
STRONG EVIDENCE	Convincing		Body fatness <sup>1</sup>
	Probable		Adult attained height <sup>2</sup>
LIMITED EVIDENCE	Limited – suggestive		Red meat <sup>3</sup> Processed meat <sup>4</sup> Alcoholic drinks (heavier drinking) <sup>5</sup> Foods and beverages containing fructose <sup>6</sup> Foods containing saturated fatty acids
	Limited – no conclusion	Physical activity; fruits; vegetables; folate; fish; eggs; tea; soft drinks; coffee; carbohydrates; sucrose; glycaemic index; glycaemic load; total fat; monounsaturated fat; polyunsaturated fats; dietary cholesterol; vitamin C; and multivitamin/mineral supplements	
STRONG EVIDENCE	Substantial effect on risk unlikely		

## Diet, nutrition, physical activity and cancer: a global perspective

A summary of the Third Expert Report




2012	DIET, NUTRITION, PHYSICAL ACTIVITY AND PANCREATIC CANCER		
		DECREASES RISK	INCREASES RISK
STRONG EVIDENCE	Convincing		Body fatness <sup>1</sup>
	Probable		Adult attained height <sup>2</sup>
LIMITED EVIDENCE	Limited – suggestive		Red meat <sup>3</sup> Processed meat <sup>4</sup> Alcoholic drinks (heavier drinking) <sup>5</sup> Foods and beverages containing fructose <sup>6</sup> Foods containing saturated fatty acids
	Limited – no conclusion	Physical activity; fruits; vegetables; folate; fish; eggs; tea; soft drinks; coffee; carbohydrates; sucrose; glycaemic index; glycaemic load; total fat; monounsaturated fat; polyunsaturated fats; dietary cholesterol; vitamin C; and multivitamin/mineral supplements	
STRONG EVIDENCE	Substantial effect on risk unlikely		

**Convincing evidence**


**Body fatness: Greater body fatness is a convincing cause of pancreatic cancer.**



# Absolute risk in for a rare disease



# Absolute risk in for a rare disease




# What is the relative risk of obesity that influence pancreatic cancer?

**Table 1.** Risk Factors and Inherited Syndromes Associated with Pancreatic Cancer.\*

Variable	Approximate Risk
Risk factor	
Smoking <sup>3</sup>	2–3
Long-standing diabetes mellitus <sup>4</sup>	2
Nonhereditary and chronic pancreatitis <sup>5</sup>	2–6
Obesity, inactivity, or both <sup>6</sup>	2
Non-O blood group <sup>7</sup>	1–2
Genetic syndrome and associated gene or genes — %	
Hereditary pancreatitis ( <i>PRSS1</i> , <i>SPINK1</i> ) <sup>8</sup>	50
Familial atypical multiple mole and melanoma syndrome ( <i>p16</i> ) <sup>9</sup>	10–20
Hereditary breast and ovarian cancer syndromes ( <i>BRCA1</i> , <i>BRCA2</i> , <i>PALB2</i> ) <sup>10,11</sup>	1–2
Peutz–Jeghers syndrome ( <i>STK11</i> [ <i>LKB1</i> ]) <sup>12</sup>	30–40
Hereditary nonpolyposis colon cancer (Lynch syndrome) ( <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> ) <sup>13</sup>	4
Ataxia–telangiectasia ( <i>ATM</i> ) <sup>14</sup>	Unknown
Li–Fraumeni syndrome ( <i>P53</i> ) <sup>15</sup>	Unknown

\* Values associated with risk factors are expressed as relative risks, and values associated with genetic syndromes are expressed as lifetime risks, as compared with the risk in the general population.






# What is the relative risk of obesity that influence pancreatic cancer?

**Table 1.** Risk Factors and Inherited Syndromes Associated with Pancreatic Cancer.\*

Variable	Approximate Risk
Risk factor	
Smoking <sup>3</sup>	2–3
Long-standing diabetes mellitus <sup>4</sup>	2
Nonhereditary and chronic pancreatitis <sup>5</sup>	2–6
Obesity, inactivity, or both <sup>6</sup>	2
Non-O blood group <sup>7</sup>	1–2
Genetic syndrome and associated gene or genes — %	
Hereditary pancreatitis ( <i>PRSS1</i> , <i>SPINK1</i> ) <sup>8</sup>	50
Familial atypical multiple mole and melanoma syndrome ( <i>p16</i> ) <sup>9</sup>	10–20
Hereditary breast and ovarian cancer syndromes ( <i>BRCA1</i> , <i>BRCA2</i> , <i>PALB2</i> ) <sup>10,11</sup>	1–2
Peutz–Jeghers syndrome ( <i>STK11</i> [ <i>LKB1</i> ]) <sup>12</sup>	30–40
Hereditary nonpolyposis colon cancer (Lynch syndrome) ( <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> ) <sup>13</sup>	4
Ataxia–telangiectasia ( <i>ATM</i> ) <sup>14</sup>	Unknown
Li–Fraumeni syndrome ( <i>P53</i> ) <sup>15</sup>	Unknown

\* Values associated with risk factors are expressed as relative risks, and values associated with genetic syndromes are expressed as lifetime risks, as compared with the risk in the general population.

Obesity



# Obesity is a Modifiable PDAC Risk Factor

	Risk factor	Increased PDAC risk
Smoking	Current cigarette use	1.7-2.2
	Current pipe or cigar use	1.5
Alcohol	> 3 alcoholic drinks per day	1.2-1.4
	Chronic pancreatitis	13.3
Obesity	BMI > 40 kg/m <sup>2</sup> , male	1.5
	BMI > 40 kg/m <sup>2</sup> , female	2.8
Diabetes	Diabetes mellitus, type 1	2.0
	Diabetes mellitus, type 2	1.8
	Cholecystectomy	1.2
	Gastrectomy	1.5
	<i>Helicobacter pylori</i> infection	1.4

PDAC: Pancreatic ductal adenocarcinomas; BMI: Body mass index.

# Obesity is a Modifiable PDAC Risk Factor

	Risk factor	Increased PDAC risk
<b>Smoking</b>	Current cigarette use	1.7-2.2
	Current pipe or cigar use	1.5
<b>Alcohol</b>	> 3 alcoholic drinks per day	1.2-1.4
	Chronic pancreatitis	13.3
<b>Obesity</b>	BMI > 40 kg/m <sup>2</sup> , male	1.5
	BMI > 40 kg/m <sup>2</sup> , female	2.8
<b>Diabetes</b>	Diabetes mellitus, type 1	2.0
	Diabetes mellitus, type 2	1.8
	Cholecystectomy	1.2
	Gastrectomy	1.5
	<i>Helicobacter pylori</i> infection	1.4




Can we prevent?



PDAC: Pancreatic ductal adenocarcinomas; BMI: Body mass index.

# Projected Increase in Pancreatic Cancer Deaths by 2030 Thought to Correlate with Obesity Trends



Perspective


Cancer  
Research

**Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States**

Lola Rahib<sup>1</sup>, Benjamin D. Smith<sup>2</sup>, Rhonda Aizenberg<sup>1</sup>, Allison B. Rosenzweig<sup>1</sup>, Julie M. Fleshman<sup>1</sup>, and Lynn M. Matrisian<sup>1</sup>

Cancer Res; 74(11) June 1, 2014

# Projected Increase in Pancreatic Cancer Deaths by 2030 Thought to Correlate with Obesity Trends



Perspective

Cancer  
Research


**Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States**

Lola Rahib<sup>1</sup>, Benjamin D. Smith<sup>2</sup>, Rhonda Aizenberg<sup>1</sup>, Allison B. Rosenzweig<sup>1</sup>, Julie M. Fleshman<sup>1</sup>, and Lynn M. Matrisian<sup>1</sup>


Cancer Res; 74(11) June 1, 2014

# Projected Increase in Pancreatic Cancer Deaths by 2030 Thought to Correlate with Obesity Trends

Cancer Incidence in the United States



Obesity Trend in the United States



Perspective

Cancer Research

**Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States**

Lola Rahib<sup>1</sup>, Benjamin D. Smith<sup>2</sup>, Rhonda Aizenberg<sup>1</sup>, Allison B. Rosenzweig<sup>1</sup>, Julie M. Fleshman<sup>1</sup>, and Lynn M. Matrisian<sup>1</sup>

Cancer Res; 74(11) June 1, 2014


## Obesity and Severe Obesity Forecasts Through 2030

Eric A. Finkelstein, PhD, MHA, Olga A. Khavjou, MA, Hope Thompson, BA, Justin G. Trogon, PhD, Liping Pan, MD, MPH, Bettylou Sherry, PhD, RD, William Dietz, MD, PhD

Am J Prev Med 2012;42(6):563–570




# The shape of things to come



12/11/2013

The  
Economist

# Obesity is a Worldwide Epidemic in Adults and Children




# Obesity Trends Increasing in the United States

## Adult Obesity Rate by State, 1990

Select years with the slider to see historical data. Hover over states for more information. Click a state to lock the selection. Click again to unlock.

Percent of obese adults (Body Mass Index of 30+)




# Obesity Trends Increasing in the United States

## Adult Obesity Rate by State, 1990

Select years with the slider to see historical data. Hover over states for more information. Click a state to lock the selection. Click again to unlock.


Percent of obese adults (Body Mass Index of 30+)



## Adult Obesity Rate by State, 2017

Select years with the slider to see historical data. Hover over states for more information. Click a state to lock the selection. Click again to unlock.


Percent of obese adults (Body Mass Index of 30+)



# Obesity Trends Increasing in the United States


Rank	State	Adult Obesity Rate 2017	95% Confidence Interval	Trend 1990 - 2017
1	West Virginia	38.1%	+/- 1.7%	
2	Mississippi	37.3%	+/- 2.0%	
3	Oklahoma	36.5%	+/- 1.6%	
4	Iowa	36.4%	+/- 1.3%	
5	Alabama	36.3%	+/- 1.6%	
6	Louisiana	36.2%	+/- 1.8%	
7	Arkansas	35.0%	+/- 2.4%	
8	Kentucky	34.3%	+/- 1.7%	
9	Alaska	34.2%	+/- 2.9%	
10	South Carolina	34.1%	+/- 1.3%	
11	Ohio	33.8%	+/- 1.3%	
12	Indiana	33.6%	+/- 1.1%	
13	North Dakota	33.2%	+/- 1.6%	
14	Texas	33.0%	+/- 1.8%	
15	Nebraska	32.8%	+/- 1.2%	
15	Tennessee	32.8%	+/- 1.8%	
17	Missouri	32.5%	+/- 1.5%	
18	Kansas	32.4%	+/- 0.8%	
19	Michigan	32.3%	+/- 1.2%	
20	North Carolina	32.1%	+/- 1.8%	

# 15 Types of Cancer have being directly linked to being overweight or obese.





# Obesity is a Risk Factor for Many Cancers



## OBESITY AND OVERWEIGHT INCREASING WORLDWIDE

**3.4**  
**million**

**DEATHS CAUSED  
by overweight  
AND OBESITY**



**Obesity and overweight  
INCREASED  
27.5% IN ADULTS  
47.1% IN CHILDREN  
SINCE 1980**

## OBESITY AND OVERWEIGHT INCREASING WORLDWIDE


**3.4**  
**million**

**DEATHS CAUSED  
by overweight  
AND OBESITY**



**Obesity and overweight  
INCREASED  
27.5% IN ADULTS  
47.1% IN CHILDREN  
SINCE 1980**

Middle Eastern countries experiencing some of the largest increases in obesity globally:  
**SAUDI ARABIA, BAHRAIN, EGYPT,  
KUWAIT, AND PALESTINE**




## OBESITY AND OVERWEIGHT INCREASING WORLDWIDE

**3.4**  
**million**

**DEATHS CAUSED  
by overweight  
AND OBESITY**

Middle Eastern countries experiencing some of the largest increases in obesity globally:  
**SAUDI ARABIA, BAHRAIN, EGYPT,  
KUWAIT, AND PALESTINE**



**Obesity and overweight  
INCREASED  
27.5% IN ADULTS  
47.1% IN CHILDREN  
SINCE 1980**

**37**

Percentage of the  
world's adult population  
that is overweight  
or obese

**0**

Number of countries  
succeeding in  
decreasing obesity  
in last 33 years

**14**

Percentage of  
overweight or obese  
children and adolescents  
worldwide

**62**

Percentage of the  
world's obese living  
in developing countries

THE US ACCOUNTS FOR **13%** OF THE NUMBER OF OBESE PEOPLE  
GLOBALLY BUT **JUST 5%** OF THE WORLD'S POPULATION

**OBESITY AND OVERWEIGHT CONTRIBUTE TO:**



• **CARDIOVASCULAR DISEASE**



• **DIABETES**




• **CANCER**



• **JOINT PAIN**

# Obesity is Associated with Increased Healthcare Utilization in Hospitalized Patients with Pancreatic Cancer



## Patient group:

Inclusion criteria:

**A secondary diagnosis of pancreatic cancer**

(ICD-9 codes: 157.0, 157.1, 157.2, 157.3, 157.4, 157.8, 157.9)

Exclusion criteria:

Age less than 18 years

Admission in the month of December

## Exposure of interest:

- Obesity: 278.00, 278.01, V853, V85.30-V85.39, V85.4, V854.1-V854.5.
- Subgroup analysis: Morbid obesity: V85.4, V854.1-V854.5, 278.01

# Normal Weight vs Obese Pancreatic Cancer-Related Hospitalizations


	Normal weight	Obese	P-value	Adjusted mean difference *
<b>Mortality rate</b>	7.7% (7.2-8.3)	7.5% (5.8-9.6)	0.7878	1.00 (0.75-1.34) P=0.98 Adjusted odds
<b>Mean length of stay</b>	5.6 days (5.5-5.74)	6.8 days (6.4-7.3)	< 0.01	1.19 days (0.72-1.66) P<0.01
<b>Mean hospitalization charges</b>	\$48,337 (\$46,300-\$50,373)	\$61,056 (\$55,411-\$66,700)	< 0.01	\$13,432 (\$7,848-\$19,016) P<0.01
<b>Mean hospitalization costs</b>	\$12,489 (\$12,091-\$12,889)	\$15,652 (\$14,386-\$16,919)	< 0.01	\$3,311 (\$2,022 - \$4,599) P<0.01
<b>Palliative care consult for metastatic pancreatic cancer</b>	19.3% (18.2%-20.4%)	20.8% (17.2%-24.9%)	0.44	0.89 (0.72-1.11) P=0.32




# Obese vs Morbidly Obese Pancreatic Cancer-Related Hospitalizations

	Obese	Morbidly Obese	P-value	Adjusted mean difference *
<b>Mortality rate</b>	7.7% (7.2-8.2)	8.8 % (6.0-12.8)	0.4867	1.16 (0.75-1.79) P=0.496 Adjusted odds
<b>Mean length of stay</b>	5.6 days (5.8-5.7)	7.4 days (6.6-8.2)	<b>&lt; 0.01</b>	1.79 (1.02-2.57) P<0.01
<b>Mean hospitalization charges</b>	\$48,672 (\$46,660-\$50,684)	\$67,726 (\$57,824 - \$77,627)	<b>&lt; 0.01</b>	\$20,528 (\$10,735-\$30,321) P<0.01
<b>Mean hospitalization costs</b>	\$12,599 (\$12,200-\$12,997)	\$16,215 (\$14,470-\$17,961)	<b>&lt; 0.01</b>	\$3,986 (\$2,197 - \$5,774) P<0.01
<b>Palliative care consult for metastatic pancreatic cancer</b>	19.3% (18.2%-20.4%)	25.3% (19.1%-32.8%)	P =0.0575	1.11 (0.82-1.52) P=0.49

# How to measure obesity?




# How to measure obesity?



## Skinfold Thickness




# How to measure obesity?



Skinfold Thickness      Waist Circumference



# How to measure obesity?




Skinfold Thickness




Waist Circumference



Waist : Hip Ratio



# How to measure obesity?




Skinfold Thickness



Waist Circumference





Waist : Hip Ratio





# What are the Molecular Mechanisms that Increase the Risk of PDAC Development in Obese Individuals?



Stroma is about  
90% of tumor volume

# What are the Molecular Mechanisms that Increase the Risk of PDAC Development in Obese Individuals?

**Obesity-Associated  
Cancer In Mice**



**Obesity-Associated  
Cancer In Humans**




# What are the Molecular Mechanisms that Increase the Risk of PDAC Development in Obese Individuals?


Obesity-Associated  
Cancer In Mice



Obesity-Associated  
Cancer In Humans




# Adipose tissue depots in mice vs humans







# Adipose tissue depots in mice vs humans



# Adipose tissue depots occur throughout the body




Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease, Volume: 118, Issue: 11, Pages: 1786-1807, DOI: (10.1161/CIRCRESAHA.115.306885)




Horm Mol Biol Clin Invest 2014; 19(1): 57-74

# Three types of adipocyte: brown, white and beige (brite)










# Three types of adipocyte: brown, white and beige (brite)




Control of brown and beige fat development

Wenshan Wang and Patrick Seale


# “Crown-like” structures of immune cells defined adipose tissue inflammation




# White adipose tissue is essential for survival



# Adipose Stromal Cells are Multipotent




# What Factors from the Adipose Tissue Contribute to the Development and Progression of PDAC?






# What Factors from the Adipose Tissue Contribute to the Development and Progression of PDAC?



# Factors Related to Obesity Affecting PDAC






# Factors Related to Obesity Affecting PDAC


## Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma

Mika Hori, PhD<sup>1</sup>, Mami Takahashi, PhD<sup>2</sup>, Nobuyoshi Hiraoka, MD, PhD<sup>3</sup>, Taiki Yamaji, MD, PhD, MPH<sup>4</sup>, Michihiro Mutoh, MD, PhD<sup>5</sup>, Rikako Ishigamori, PhD<sup>5</sup>, Koh Furuta, MD, PhD<sup>6</sup>, Takuji Okusaka, MD, PhD<sup>7</sup>, Kazuaki Shimada, MD, PhD<sup>8</sup>, Tomoo Kosuge, MD, PhD<sup>9</sup>, Yae Kanai, MD, PhD<sup>3</sup> and Hitoshi Nakagawa, MD, DMSc<sup>1,5</sup>


Clinical and Translational Gastroenterology (2014) 5, e53.




# Factors Related to Obesity Affecting PDAC




# Factors Related to Obesity Affecting PDAC



# Factors Related to Obesity Affecting PDAC



# Factors Related to Obesity Affecting PDAC





# Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy<sup>AC</sup>

Joao Inacio<sup>1,2,3</sup>, Hao Liu<sup>4</sup>\*, Priya Suboil<sup>5</sup>, Shan M. Chin<sup>1</sup>, Ivy X. Chen<sup>1,6</sup>, Matthias Pinter<sup>1</sup>, Mei R. Ng<sup>1</sup>, Hadi T. Nia<sup>1</sup>, Jelena Grahovac<sup>1</sup>, Shannon Kao<sup>1</sup>, Suboj Babykutty<sup>1,7</sup>, Yuhui Huang<sup>1</sup>, Keehoon Jung<sup>1</sup>, Nuh N. Rehbari<sup>1</sup>, Xiaobing Han<sup>1</sup>, Vikash P. Chauhan<sup>1</sup>, John D. Martin<sup>1</sup>, Julia Kahn<sup>1</sup>, Peigen Huang<sup>1</sup>, Vikram Deshpande<sup>8</sup>, James Michaelson<sup>9,8</sup>, Theodoros P. Michalakos<sup>10</sup>, Cristina R. Ferrone<sup>8,10</sup>, Raquel Soares<sup>1</sup>, Yves Boucher<sup>1</sup>, Dai Fukumura<sup>1</sup>, and Rakesh K. Jain<sup>1</sup>

CANCER DISCOVERY | 853



# Factors Related to Obesity Affecting PDAC

## Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma

Mika Hori, PhD<sup>1</sup>, Mami Takahashi, PhD<sup>2</sup>, Nobuyoshi Hiraoka, MD, PhD<sup>3</sup>, Taiki Yamaji, MD, PhD, MPH<sup>4</sup>, Michihiro Mutoh, MD, PhD<sup>2</sup>, Rikako Ishigamori, PhD<sup>2</sup>, Koh Furuta, MD, PhD<sup>2</sup>, Takuji Okusaka, MD, PhD<sup>2</sup>, Kazuaki Shimada, MD, PhD<sup>2</sup>, Tomoo Kosuge, MD, PhD<sup>2</sup>, Yae Kanai, MD, PhD<sup>2</sup> and Hitoshi Nakagawa, MD, DMSc<sup>1,5</sup>

Clinical and Translational Gastroenterology (2014) 5, e53.

## Inflammation and mitochondrial fatty acid $\beta$ -oxidation link obesity to early tumor promotion

J. Khasawneh<sup>a</sup>, M. D. Schulz<sup>a</sup>, A. Walch<sup>b</sup>, J. Rozman<sup>c</sup>, M. Hrabe de Angelis<sup>d</sup>, M. Klingenspor<sup>d</sup>, A. Buck<sup>e</sup>, M. Schwaiger<sup>a</sup>, D. Saur<sup>a</sup>, R. M. Schmid<sup>a</sup>, G. Klöppel<sup>f</sup>, B. Sipos<sup>g</sup>, F. R. Greten<sup>a</sup>, and M. C. Arkan<sup>a,1</sup>

PNAS | March 3, 2009 | vol. 106 | no. 9

## Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer

Kathleen M. Hertzler, MD, PhD,\* Mu Xu, MD, PhD,\* Aune Moro, MSc,\* David W. Dawson, MD, PhD,\* Lin Du, MS,\* Gang Li, PhD,\* Hui-Hua Chang, PhD,\* Alexander P. Stark, MD,\* Xiaoman Jung, MD,\* Oscar Joe Hines, MD,\* and Guido Eibl, MD\*

Pancreas • Volume 45, Number 3, March 2016

## Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms

Ana Babic<sup>1</sup>, Ying Bao<sup>2</sup>, Zhi Rong Qian<sup>1</sup>, Chen Yuan<sup>1</sup>, Edward L. Giovannucci<sup>2,3,4</sup>, Hugues Aschard<sup>2</sup>, Peter Kraft<sup>3,5</sup>, Laufey T. Amundadottir<sup>6</sup>, Rachael Stolzenberg-Solomon<sup>7</sup>, Vicente Morales-Oyarvide<sup>1</sup>, Kimmie Ng<sup>1</sup>, Meir J. Stampfer<sup>2,3,4</sup>, Shuji Ogino<sup>1,8</sup>, Julie E. Buring<sup>9,10</sup>, Howard D. Sesso<sup>3,9</sup>, John Michael Gaziano<sup>9,11</sup>, Nader Rifai<sup>12</sup>, Michael N. Pollak<sup>13</sup>, Matthew L. Anderson<sup>14</sup>, Barbara B. Cochrane<sup>15</sup>, Juhua Luo<sup>16</sup>, JoAnn E. Manson<sup>2,3,13</sup>, Charles S. Fuchs<sup>1,2</sup>, and Brian M. Wolpin<sup>1</sup>

Cancer Res; 76(24) December 15, 2016

## Modulation of the Leptin Receptor Mediates Tumor Growth and Migration of Pancreatic Cancer Cells

Alisha M. Mendonsa<sup>1\*</sup>, Madeleine C. Chalfant<sup>1</sup>, Lee D. Gorden<sup>1,2</sup>, Michael N. VanSaun<sup>3\*\*</sup>

PLOS ONE | DOI:10.1371/journal.pone.0126686 April 28, 2015

## Dietary Energy Balance Modulation of Kras- and Ink4a/Arf<sup>+/+</sup>-Driven Pancreatic Cancer: The Role of Insulin-like Growth Factor-I

Laura M. Lashinger<sup>1</sup>, Lauren M. Harrison<sup>1</sup>, Audrey J. Rasmussen<sup>1</sup>, Craig D. Logsdon<sup>2</sup>, Susan M. Fischer<sup>3</sup>, Mark J. McArthur<sup>3,4</sup>, and Stephen D. Hursting<sup>1,3</sup>

Cancer Prev Res; 6(10) October 2013

## Arginase

Tamara Zaytouni<sup>1,2,3</sup>, Pei-Yun Tsai<sup>1,2</sup>, Daniel S. Hitchcock<sup>3</sup>, Cory D. DuBois<sup>1,3</sup>, Elizaveta Freinkman<sup>4,8</sup>, Lin Lin<sup>2</sup>, Vicente Morales-Oyarvide<sup>5</sup>, Patrick J. Lenehan<sup>1,2</sup>, Brian M. Wolpin<sup>5</sup>, Mari Mino-Kenudson<sup>6</sup>, Eduardo M. Torres<sup>7</sup>, Nicholas Stylianopoulos<sup>1,2,3</sup>, and Guido Eibl<sup>1,2,3</sup>

NATURE COMMUNICATIONS | 8:242

## Obesity

## Pancreatic Fatty Infiltration

## Inflammation

## Lipocalin-2 (LCN2/NGAL)

## COX2

## Resistance to Chemotherapy

## IGF-1

## Arginase

## A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,8</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,8</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas; <sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Białystok, Białystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

GASTROENTEROLOGY 2013;145:1449-1458

## Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy

Joao Inacio<sup>1,2,3</sup>, Hao Liu<sup>1,4</sup>, Priya Subbaj<sup>1,5</sup>, Shan M. Chin<sup>1</sup>, Ivy X. Chen<sup>1,6</sup>, Matthias Pinter<sup>1</sup>, Mei R. Ng<sup>1</sup>, Hadi T. Nia<sup>1</sup>, Jelena Grahovac<sup>1</sup>, Shannon Kao<sup>1</sup>, Suboj Babykutty<sup>1,7</sup>, Yuhui Huang<sup>1</sup>, Keehoon Jung<sup>1</sup>, Nuh N. Rahbari<sup>1</sup>, Xiaoxing Han<sup>1</sup>, Vikash P. Chauhan<sup>1</sup>, John D. Martin<sup>1</sup>, Julia Kahn<sup>1</sup>, Peigen Huang<sup>1</sup>, Vikram Deshpande<sup>8</sup>, James Michaelson<sup>8,9</sup>, Theodoros P. Michalakis<sup>10</sup>, Cristina R. Ferrone<sup>8,10</sup>, Raquel Soares<sup>3</sup>, Yves Boucher<sup>1</sup>, Dai Fukumura<sup>1</sup>, and Rakesh K. Jain<sup>1</sup>

CANCER DISCOVERY | 853



# Factors Related to Obesity Affecting PDAC

Molecular and Cellular Pathobiology

Cancer Research

## Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment

Sobeyda B. Gomez-Chou<sup>1</sup>, Agnieszka Katarzyna Swidnicka-Siergiejko<sup>1,2</sup>, Niharika Badi<sup>3,4,5</sup>, Myriah Chavez-Tomar<sup>3,4,5</sup>, Gregory B. Lesinski<sup>6</sup>, Tanios Bekali-Saab<sup>7</sup>, Matthew R. Farren<sup>8</sup>, Thomas A. Mace<sup>9</sup>, Carl Schmidt<sup>10</sup>, Yan Liu<sup>11</sup>, Defeng Deng<sup>10,11</sup>, Rosa F. Hwang<sup>12</sup>, Liran Zhou<sup>13</sup>, Todd Moore<sup>14</sup>, Deyali Chatterjee<sup>10</sup>, Huamin Wang<sup>10,11</sup>, Xiaohong Leng<sup>11</sup>, Ralph B. Arlinghaus<sup>11</sup>, Craig D. Logsdon<sup>10,12</sup>, and Zobeida Cruz-Monserrate<sup>3,4,5</sup>

Cancer Res; 77(10) May 15, 2017



Lipocalin-2 (LCN2/NGAL)

## Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma

Mika Hori, PhD<sup>1</sup>, Mami Takahashi, PhD<sup>2</sup>, Nobuyoshi Hiraoka, MD, PhD<sup>3</sup>, Taiki Yamaji, MD, PhD, MPH<sup>4</sup>, Michihiro Mutoh, MD, PhD<sup>5</sup>, Rikako Ishigamori, PhD<sup>6</sup>, Koh Furuta, MD, PhD<sup>7</sup>, Takuji Okusaka, MD, PhD<sup>7</sup>, Kazuaki Shimada, MD, PhD<sup>8</sup>, Tomoo Kosuge, MD, PhD<sup>9</sup>, Yae Kanai, MD, PhD<sup>3</sup> and Hitoshi Nakagawa, MD, DMSc<sup>1,5</sup>

Clinical and Translational Gastroenterology (2014) 5, e53.

Pancreatic Fatty Infiltration

## Inflammation and mitochondrial fatty acid $\beta$ -oxidation link obesity to early tumor promotion

J. Khasawneh<sup>a</sup>, M. D. Schulz<sup>a</sup>, A. Walch<sup>b</sup>, J. Rozman<sup>c</sup>, M. Hrabe de Angelis<sup>d</sup>, M. Klingenspor<sup>d</sup>, A. Buck<sup>e</sup>, M. Schwaiger<sup>a</sup>, D. Saur<sup>a</sup>, R. M. Schmid<sup>a</sup>, G. Klöppel<sup>f</sup>, B. Sipos<sup>f</sup>, F. R. Greten<sup>a</sup>, and M. C. Arkan<sup>a,1</sup>

PNAS | March 3, 2009 | vol. 106 | no. 9

## Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer

Kathleen M. Hertzler, MD, PhD,\* Mu Xu, MD, PhD,\* Aune Moro, MSc,\* David W. Dawson, MD, PhD,† Lin Du, MS,‡ Gang Li, PhD,‡ Hui-Hua Chang, PhD,\* Alexander P. Stark, MD,\* Xiaoman Jung, MD,\* Oscar Joe Hines, MD,\* and Guido Eibl, MD\*

Pancreas • Volume 45, Number 3, March 2016

## A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,8</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,8</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas; <sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Białystok, Białystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

GASTROENTEROLOGY 2013;145:1449-1458

COX2

Obesity

Leptin

Cancer Res; 76(24) December 15, 2016

## Modulation of the Leptin Receptor Mediates Tumor Growth and Migration of Pancreatic Cancer Cells

Alisha M. Mendonsa<sup>1\*</sup>, Madeleine C. Chalfant<sup>1</sup>, Lee D. Gorden<sup>1,2</sup>, Michael N. VanSaun<sup>3\*\*</sup>

PLOS ONE | DOI:10.1371/journal.pone.0126686 April 28, 2015

## Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy

Joao Inacio<sup>1,2,3</sup>, Hao Liu<sup>1,4</sup>, Priya Subbaj<sup>1,5</sup>, Shan M. Chin<sup>1</sup>, Ivy X. Chen<sup>1,6</sup>, Matthias Pinter<sup>1</sup>, Mei R. Ng<sup>1</sup>, Hadi T. Nia<sup>1</sup>, Jelena Grahovac<sup>1</sup>, Shannon Kao<sup>1</sup>, Suboj Babykutty<sup>1,7</sup>, Yuhui Huang<sup>1</sup>, Keehoon Jung<sup>1</sup>, Nuh N. Rahbari<sup>1</sup>, Xiaoxing Han<sup>1</sup>, Vikash P. Chauhan<sup>1</sup>, John D. Martin<sup>1</sup>, Julia Kahn<sup>1</sup>, Peigen Huang<sup>1</sup>, Vikram Deshpande<sup>8</sup>, James Michaelson<sup>8,9</sup>, Theodoros P. Michalakos<sup>10</sup>, Cristina R. Ferrone<sup>8,10</sup>, Raquel Soares<sup>3</sup>, Yves Boucher<sup>1</sup>, Dai Fukumura<sup>1</sup>, and Rakesh K. Jain<sup>1</sup>

CANCER DISCOVERY | 853

Resistance to Chemotherapy

IGF-1

## Dietary Energy Balance Modulation of Kras- and Ink4a/Arf<sup>+/+</sup>-Driven Pancreatic Cancer: The Role of Insulin-like Growth Factor-I

Laura M. Lashinger<sup>1</sup>, Lauren M. Harrison<sup>1</sup>, Audrey J. Rasmussen<sup>1</sup>, Craig D. Logsdon<sup>2</sup>, Susan M. Fischer<sup>3</sup>, Mark J. McArthur<sup>3,4</sup>, and Stephen D. Hursting<sup>1,3</sup>

Cancer Prev Res; 6(10) October 2013

Arginase

## Critical role for arginase 2 in obesity-associated pancreatic cancer

Tamara Zaytouni<sup>1,2,3</sup>, Pei-Yun Tsai<sup>1,2</sup>, Daniel S. Hitchcock<sup>3</sup>, Cory D. DuBois<sup>1,3</sup>, Elizaveta Freinkman<sup>4,8</sup>, Lin Lin<sup>2</sup>, Vicente Morales-Oyarvide<sup>5</sup>, Patrick J. Lenehan<sup>1,2</sup>, Brian M. Wolpin<sup>5</sup>, Mari Mino-Kenudson<sup>6</sup>, Eduardo M. Torres<sup>7</sup>, Nicholas Stylianopoulos<sup>1,2,3</sup>, and Guido Eibl<sup>1,2,3</sup>

NATURE COMMUNICATIONS | 8:242

# Obesity-Induced PDAC in Genetically Engineered Mouse Models (GEMM)

## Inflammation and mitochondrial fatty acid $\beta$ -oxidation link obesity to early tumor promotion

J. Khasawneh<sup>a</sup>, M. D. Schulz<sup>a</sup>, A. Walch<sup>b</sup>, J. Rozman<sup>c</sup>, M. Hrabe de Angelis<sup>c</sup>, M. Klingenspor<sup>d</sup>, A. Buck<sup>e</sup>, M. Schwaiger<sup>e</sup>, D. Saur<sup>a</sup>, R. M. Schmid<sup>a</sup>, G. Klöppel<sup>f</sup>, B. Sipos<sup>f</sup>, F. R. Greten<sup>a</sup>, and M. C. Arkan<sup>a,1</sup>

PNAS | March 3, 2009 | vol. 106 | no. 9

[Chow vs HFD Research Diets lard](#)

## High-Fat, High-Calorie Diet Promotes Early Pancreatic Neoplasia in the Conditional Kras<sup>G12D</sup> Mouse Model

David W. Dawson<sup>1,5</sup>, Kathleen Hertzner<sup>2</sup>, Aune Moro<sup>2</sup>, Graham Donald<sup>2</sup>, Hui-Hua Chang<sup>2</sup>, Vay Liang Go<sup>3</sup>, Steven J. Pandol<sup>3,6,7</sup>, Aurelia Lugea<sup>3,6</sup>, Anna S. Gukovskaya<sup>3,6</sup>, Gang Li<sup>4,5</sup>, Oscar J. Hines<sup>2,5</sup>, Enrique Rozengurt<sup>3,5</sup>, and Guido Eibl<sup>2,5</sup>

Cancer Prev Res; 6(10) October 2013

[12% or a 40% fat diet AIN-76A, HFCD Corn oil](#)

## A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GO BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,§</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,§</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas;

<sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

GASTROENTEROLOGY 2013;145:1449–1458

[10% or a 60% fat diet Test Diet DIO 58Y2 and DIO 58Y1; Lab Supply lard](#)


AUGUST 2016 CANCER DISCOVERY | 853

## Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy<sup>AC</sup>

Joao Inacio<sup>1,2,3</sup>, Hao Liu<sup>1,4</sup>, Priya Suboj<sup>1,5</sup>, Shan M. Chin<sup>1</sup>, Ivy X. Chen<sup>1,6</sup>, Matthias Pinter<sup>1</sup>, Mei R. Ng<sup>1</sup>, Hadi T. Nia<sup>1</sup>, Jelena Grahovac<sup>1</sup>, Shannon Kao<sup>1</sup>, Suboj Babykutty<sup>1,7</sup>, Yuhui Huang<sup>1</sup>, Keehoon Jung<sup>1</sup>, Nuh N. Rahbari<sup>1</sup>, Xiaoxing Han<sup>1</sup>, Vikash P. Chauhan<sup>1</sup>, John D. Martin<sup>1</sup>, Julia Kahn<sup>1</sup>, Peigen Huang<sup>1</sup>, Vikram Deshpande<sup>8</sup>, James Michaelson<sup>8,9</sup>, Theodoros P. Michelakos<sup>10</sup>, Cristina R. Ferrone<sup>8,10</sup>, Raquel Soares<sup>2</sup>, Yves Boucher<sup>1</sup>, Dai Fukumura<sup>1</sup>, and Rakesh K. Jain<sup>1</sup>

[10% or a 60% fat diet \(D12450J and D12492; Research Diets\) lard](#)


# Obesity-Induced PDAC in Genetically Engineered Mouse Models (GEMM)



Caloric Breakdown	% kcal of each nutrient	
	Control Diet	High Fat Diet
Protein	18.3	18.1
Fat	10.2	61.6
Carbohydrate	71.5	20.3

Isocaloric


# Obesity-Induced PDAC in Genetically Engineered Mouse Models (GEMM)



	% kcal of each nutrient	
Caloric Breakdown	Control Diet	High Fat Diet
Protein	18.3	18.1
Fat	10.2	61.6
Carbohydrate	71.5	20.3

Isocaloric

Energy Protein Fat Fiber kcal chow and purified





# A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,§</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,§</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas;

<sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

GASTROENTEROLOGY 2013;145:1449-1458






# A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,§</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,§</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas;

<sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

GASTROENTEROLOGY 2013;145:1449-1458





# A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,§</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,§</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas;

<sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

GASTROENTEROLOGY 2013;145:1449-1458






# A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,§</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,§</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas;

<sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

**GASTROENTEROLOGY 2013;145:1449-1458**





# A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,§</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,§</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas;

<sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

GASTROENTEROLOGY 2013;145:1449-1458





# A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,§</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,§</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas;

<sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

GASTROENTEROLOGY 2013;145:1449-1458




# A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,§</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,§</sup>

<sup>1</sup>Department of Cancer Biology, <sup>2</sup>Surgical Oncology, <sup>3</sup>Pathology, <sup>4</sup>GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas;

<sup>5</sup>Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland; and <sup>6</sup>Mayo Clinic, Rochester, Minnesota

GASTROENTEROLOGY 2013;145:1449-1458





# Factors Related to Obesity Affecting PDAC

Molecular and Cellular Pathobiology

Cancer Research

## Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment

Sobeyda B. Gomez-Chou<sup>1</sup>, Agnieszka Katarzyna Swidnicka-Siergiejko<sup>1,2</sup>, Niharika Badi<sup>3,4,5</sup>, Myriah Chavez-Tomar<sup>3,4,5</sup>, Gregory B. Lesinski<sup>6</sup>, Tanios Bekali-Saab<sup>7</sup>, Matthew R. Farren<sup>8</sup>, Thomas A. Mace<sup>9</sup>, Carl Schmidt<sup>4</sup>, Yan Liu<sup>1</sup>, Defeng Deng<sup>1</sup>, Rosa F. Hwang<sup>10</sup>, Liran Zhou<sup>9</sup>, Todd Moore<sup>9</sup>, Deyali Chatterjee<sup>10</sup>, Huamin Wang<sup>10,11</sup>, Xiaohong Leng<sup>11</sup>, Ralph B. Arlinghaus<sup>11</sup>, Craig D. Logsdon<sup>1,2</sup>, and Zobeida Cruz-Monserrate<sup>3,4,5</sup>

Cancer Res; 77(10) May 15, 2017



Lipocalin-2 (LCN2/NGAL)

## Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma

Mika Hori, PhD<sup>1</sup>, Mami Takahashi, PhD<sup>2</sup>, Nobuyoshi Hiraoka, MD, PhD<sup>3</sup>, Taiki Yamaji, MD, PhD, MPH<sup>4</sup>, Michihiro Mutoh, MD, PhD<sup>5</sup>, Rikako Ishigamori, PhD<sup>5</sup>, Koh Furuta, MD, PhD<sup>5</sup>, Takuji Okusaka, MD, PhD<sup>7</sup>, Kazuaki Shimada, MD, PhD<sup>8</sup>, Tomoo Kosuge, MD, PhD<sup>9</sup>, Yae Kanai, MD, PhD<sup>3</sup> and Hitoshi Nakagawa, MD, DMSc<sup>1,5</sup>

Clinical and Translational Gastroenterology (2014) 5, e53.

Pancreatic Fatty Infiltration

## Inflammation and mitochondrial fatty acid $\beta$ -oxidation link obesity to early tumor promotion

J. Khasawneh<sup>a</sup>, M. D. Schulz<sup>a</sup>, A. Walch<sup>b</sup>, J. Rozman<sup>c</sup>, M. Hrabe de Angelis<sup>d</sup>, M. Klingenspor<sup>d</sup>, A. Buck<sup>e</sup>, M. Schwaiger<sup>a</sup>, D. Saur<sup>a</sup>, R. M. Schmid<sup>a</sup>, G. Klöppel<sup>f</sup>, B. Sipos<sup>f</sup>, F. R. Greten<sup>a</sup>, and M. C. Arkan<sup>a,1</sup>

PNAS | March 3, 2009 | vol. 106 | no. 9

## Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer

Kathleen M. Hertzler, MD, PhD,\* Mu Xu, MD, PhD,\* Aune Moro, MSc,\* David W. Dawson, MD, PhD,† Lin Du, MS,‡ Gang Li, PhD,‡ Hui-Hua Chang, PhD,\* Alexander P. Stark, MD,\* Xiaoman Jung, MD,\* Oscar Joe Hines, MD,\* and Guido Eibl, MD\*

Pancreas • Volume 45, Number 3, March 2016

Inflammation

## A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice

BINCY PHILIP,<sup>1</sup> CHRISTINA L. ROLAND,<sup>2</sup> JAROSLAW DANILUK,<sup>5</sup> YAN LIU,<sup>1</sup> DEYALI CHATTERJEE,<sup>2</sup> SOBEYDA B. GOMEZ,<sup>1</sup> BAOAN JI,<sup>6</sup> HAOJIE HUANG,<sup>1</sup> HUAMIN WANG,<sup>3</sup> JASON B. FLEMING,<sup>2</sup> CRAIG D. LOGSDON,<sup>1,4,8</sup> and ZOBEIDA CRUZ-MONSERRATE<sup>1,8</sup>

GASTROENTEROLOGY 2013;145:1449-1458

COX2

Obesity

Leptin

## Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms

Ana Babic<sup>1</sup>, Ying Bao<sup>2</sup>, Zhi Rong Qian<sup>1</sup>, Chen Yuan<sup>1</sup>, Edward L. Giovannucci<sup>2,3,4</sup>, Hugues Aschard<sup>5</sup>, Peter Kraft<sup>3,5</sup>, Laufey T. Amundadottir<sup>6</sup>, Rachael Stolzenberg-Solomon<sup>7</sup>, Vicente Morales-Oyarvide<sup>1</sup>, Kimmie Ng<sup>1</sup>, Meir J. Stampfer<sup>2,3,4</sup>, Shuji Ogino<sup>1,8</sup>, Julie E. Buring<sup>9,10</sup>, Howard D. Sesso<sup>3,9</sup>, John Michael Gaziano<sup>9,11</sup>, Nader Rifai<sup>12</sup>, Michael N. Pollak<sup>13</sup>, Matthew L. Anderson<sup>14</sup>, Barbara B. Cochrane<sup>15</sup>, Juhua Luo<sup>16</sup>, JoAnn E. Manson<sup>2,3,13</sup>, Charles S. Fuchs<sup>1,2</sup>, and Brian M. Wolpin<sup>1</sup>

Cancer Res; 76(24) December 15, 2016

## Modulation of the Leptin Receptor Mediates Tumor Growth and Migration of Pancreatic Cancer Cells

Alisha M. Mendonsa<sup>1\*</sup>, Madeleine C. Chalfant<sup>1</sup>, Lee D. Gorden<sup>1,2</sup>, Michael N. VanSaun<sup>3\*\*</sup>

PLOS ONE | DOI:10.1371/journal.pone.0126686 April 28, 2015

IGF-1

## Dietary Energy Balance Modulation of Kras- and Ink4a/Arf<sup>+/−</sup>-Driven Pancreatic Cancer: The Role of Insulin-like Growth Factor-I

Laura M. Lashinger<sup>1</sup>, Lauren M. Harrison<sup>1</sup>, Audrey J. Rasmussen<sup>1</sup>, Craig D. Logsdon<sup>2</sup>, Susan M. Fischer<sup>3</sup>, Mark J. McArthur<sup>3,4</sup>, and Stephen D. Hursting<sup>1,3</sup>

Cancer Prev Res; 6(10) October 2013

Resistance to Chemotherapy

## Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy

Joao Inacio<sup>1,2,3</sup>, Hao Liu<sup>1,4</sup>, Priya Subbaj<sup>1,5</sup>, Shan M. Chin<sup>1</sup>, Ivy X. Chen<sup>1,6</sup>, Matthias Pinter<sup>1</sup>, Mei R. Ng<sup>1</sup>, Hadi T. Nia<sup>1</sup>, Jelena Grahovac<sup>1</sup>, Shannon Kao<sup>1</sup>, Suboj Babykutty<sup>1,7</sup>, Yuhui Huang<sup>1</sup>, Keehoon Jung<sup>1</sup>, Nuh N. Rahbari<sup>1</sup>, Xiaoxing Han<sup>1</sup>, Vikash P. Chauhan<sup>1</sup>, John D. Martin<sup>1</sup>, Julia Kahn<sup>1</sup>, Peigen Huang<sup>1</sup>, Vikram Deshpande<sup>8</sup>, James Michaelson<sup>8,9</sup>, Theodoros P. Michalakos<sup>10</sup>, Cristina R. Ferrone<sup>8,10</sup>, Raquel Soares<sup>3</sup>, Yves Boucher<sup>1</sup>, Dai Fukumura<sup>1</sup>, and Rakesh K. Jain<sup>1</sup>

CANCER DISCOVERY | 853

Arginase

## Critical role for arginase 2 in obesity-associated pancreatic cancer

Tamara Zaytouni<sup>1,2,3</sup>, Pei-Yun Tsai<sup>1,2</sup>, Daniel S. Hitchcock<sup>3</sup>, Cory D. DuBois<sup>1,3</sup>, Elizaveta Freinkman<sup>4,8</sup>, Lin Lin<sup>2</sup>, Vicente Morales-Oyarvide<sup>5</sup>, Patrick J. Lenehan<sup>1,2</sup>, Brian M. Wolpin<sup>5</sup>, Mari Mino-Kenudson<sup>6</sup>, Eduardo M. Torres<sup>7</sup>, Nicholas Stylianopoulos<sup>1,2,3</sup>, and Guido Eibl<sup>1,2,3</sup>

NATURE COMMUNICATIONS | 8:242

# Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort

*Daniel P. Schauer, MD, MSc,\* Heather Spencer Feigelson, PhD, MPH,† Corinna Koebnick, MSc, PhD,‡  
Bette Caan, DrPH,§ Sheila Weinmann, PhD, MPH,¶ Anthony C. Leonard, PhD,|| J. David Powers, MS,†  
Panduranga R. Yenumula, MD,§ and David E. Arterburn, MD, MPH\*\**



# Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort

*Daniel P. Schauer, MD, MSc,\* Heather Spencer Feigelson, PhD, MPH,† Corinna Koebnick, MSc, PhD,‡ Bette Caan, DrPH,§ Sheila Weinmann, PhD, MPH,¶ Anthony C. Leonard, PhD,|| J. David Powers, MS,† Panduranga R. Yenumula, MD,§ and David E. Arterburn, MD, MPH\*\**


**Objective:** To determine whether bariatric surgery is associated with a lower risk of cancer.

**Background:** Obesity is strongly associated with many types of cancer. Few studies have examined the relationship between bariatric surgery and cancer risk.

**Methods:** We conducted a retrospective cohort study of patients undergoing bariatric surgery between 2005 and 2012 with follow-up through 2014 using data from a large integrated health insurance and care delivery systems with 5 study sites. The study included 22,198 subjects who had bariatric surgery and 66,427 nonsurgical subjects matched on sex, age, study site, body mass index, and Elixhauser comorbidity index. Multivariable Cox proportional-hazards models were used to examine incident cancer up to 10 years after bariatric surgery compared to the matched nonsurgical patients.


# Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort

*Daniel P. Schauer, MD, MSc,\* Heather Spencer Feigelson, PhD, MPH,† Corinna Koebnick, MSc, PhD,‡  
Bette Caan, DrPH,§ Sheila Weinmann, PhD, MPH,¶ Anthony C. Leonard, PhD,|| J. David Powers, MS,†  
Panduranga R. Yenumula, MD,§ and David E. Arterburn, MD, MPH\*\**




# Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort

*Daniel P. Schauer, MD, MSc,\* Heather Spencer Feigelson, PhD, MPH,† Corinna Koebnick, MSc, PhD,‡  
Bette Caan, DrPH,§ Sheila Weinmann, PhD, MPH,¶ Anthony C. Leonard, PhD,|| J. David Powers, MS,†  
Panduranga R. Yenumula, MD,§ and David E. Arterburn, MD, MPH\*\**



# Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort


*Daniel P. Schauer, MD, MSc,\* Heather Spencer Feigelson, PhD, MPH,† Corinna Koebnick, MSc, PhD,‡  
Bette Caan, DrPH,§ Sheila Weinmann, PhD, MPH,¶ Anthony C. Leonard, PhD,|| J. David Powers, MS,†  
Panduranga R. Yenumula, MD,§ and David E. Arterburn, MD, MPH\*\**





# Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort

*Daniel P. Schauer, MD, MSc,\* Heather Spencer Feigelson, PhD, MPH,† Corinna Koebnick, MSc, PhD,‡  
Bette Caan, DrPH,§ Sheila Weinmann, PhD, MPH,¶ Anthony C. Leonard, PhD,|| J. David Powers, MS,†  
Panduranga R. Yenumula, MD,§ and David E. Arterburn, MD, MPH\*\**




**FIGURE 3.** Forest plot of multivariable Cox proportional-hazards models for obesity-associated cancers. The box represents the hazard ratio and the error bars depict the 95% confidence interval. Matching occurred on age, sex, BMI, Elixhauser comorbidity index score, and study site. The models are adjusted for race, diabetes, hyperlipidemia, hypertension, coronary artery disease, peripheral vascular disease, nonalcoholic steatohepatitis, a history of smoking, alcohol use, and use of hormone replacement therapy.



# Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort

*Daniel P. Schauer, MD, MSc,\* Heather Spencer Feigelson, PhD, MPH,† Corinna Koebnick, MSc, PhD,‡ Bette Caan, DrPH,§ Sheila Weinmann, PhD, MPH,¶ Anthony C. Leonard, PhD,|| J. David Powers, MS,† Panduranga R. Yenumula, MD,§ and David E. Arterburn, MD, MPH\*\**



**FIGURE 3.** Forest plot of multivariable Cox proportional-hazards models for obesity-associated cancers. The box represents the hazard ratio and the error bars depict the 95% confidence interval. Matching occurred on age, sex, BMI, Elixhauser comorbidity index score, and study site. The models are adjusted for race, diabetes, hyperlipidemia, hypertension, coronary artery disease, peripheral vascular disease, nonalcoholic steatohepatitis, a history of smoking, alcohol use, and use of hormone replacement therapy.

# Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort

*Daniel P. Schauer, MD, MSc,\* Heather Spencer Feigelson, PhD, MPH,† Corinna Koebnick, MSc, PhD,‡ Bette Caan, DrPH,§ Sheila Weinmann, PhD, MPH,¶ Anthony C. Leonard, PhD,|| J. David Powers, MS,† Panduranga R. Yenumula, MD,§ and David E. Arterburn, MD, MPH\*\**

**Results:** After a mean follow-up of 3.5 years, we identified 2543 incident cancers. Patients undergoing bariatric surgery had a 33% lower hazard of developing any cancer during follow-up [hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.60, 0.74,  $P < 0.001$ ] compared with matched patients with severe obesity who did not undergo bariatric surgery, and results were even stronger when the outcome was restricted to obesity-associated cancers (HR 0.59, 95% CI 0.51, 0.69,  $P < 0.001$ ). Among the obesity-associated cancers, the risk of postmenopausal breast cancer (HR 0.58, 95% CI 0.44, 0.77,  $P < 0.001$ ), colon cancer (HR 0.59, 95% CI 0.36, 0.97,  $P = 0.04$ ), endometrial cancer (HR 0.50, 95% CI 0.37, 0.67,  $P < 0.001$ ), and pancreatic cancer (HR 0.46, 95% CI 0.22, 0.97,  $P = 0.04$ ) was each statistically significantly lower among those who had undergone bariatric surgery compared with matched nonsurgical patients.

**Conclusions:** In this large, multisite cohort of patients with severe obesity, bariatric surgery was associated with a lower risk of incident cancer, particularly obesity-associated cancers, such as postmenopausal breast cancer, endometrial cancer, and colon cancer. More research is needed to clarify the specific mechanisms through which bariatric surgery lowers cancer risk.

# Knowledge Gaps

- How are factors secreted from adipose tissue affecting the tumor microenvironment of PDAC?
- Are these factors affecting cancer cells only or other cells in the tumor microenvironment?
- How is the adipose cellular microenvironment contributing to PDAC?
- Are the characteristics of an obesity-associated PDAC the same as non-obese PDAC?
- Best preclinical model that mimics human obesity-associated PDAC.
- Identify specific patient populations
  - Who are at greatest risk of developing obesity-related cancer
  - Who will benefit most from weight loss or enhanced screening
- Identify markers, metabolic intermediates or predictors of obesity-related cancer

# Paradoxical impact of obesity on cancer immunotherapy

nature  
medicine



ARTICLES

<https://doi.org/10.1038/s41591-018-0221-5>

## Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

“There is heightened immune dysfunction and tumor progression but also **greater anti-tumor efficacy and survival after checkpoint blockade** which directly targets some of the pathways activated in obesity.”

# Paradoxical impact of obesity on cancer immunotherapy




There is a statistically significant improvement in progression-free survival and overall survival in obese patients



# Impact of obesity on exhaustion and PD-1 checkpoint blockade in patients with cancer

CD3+ infiltrates in the TME of human colorectal cancers



There are significantly fewer tumor-infiltrating cells in obese patients

# Paradoxical impact of obesity on cancer immunotherapy

---

nature  
medicine

ARTICLES

<https://doi.org/10.1038/s41591-018-0221-5>

## Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

“There is heightened immune dysfunction and tumor progression but also **greater anti-tumor efficacy and survival after checkpoint blockade** which directly targets some of the pathways activated in obesity.”



# Acknowledgments

## Cruz-Monserrate Laboratory

Samantha Hazelett, MS

Kelly Dubay

Julia Dellick

Valentina Pita, MS University Fellow

Sabrina Kaul, Pelotonia Undergraduate Fellow

Olivia Ueltschi, Pelotonia Undergraduate Fellow

Ila Lahooti

Corbin Pontious

Kristyn Gumper

## GHN Clinical Coordinators

## **ZCM-Lab Summer 2019**



<http://go.osu.edu/cruz-monserrate>

<https://sites.google.com/view/zcm-lab/home>

**POSTDOCTORAL POSITION  
AVAILABLE!!!!**

## Collaborators

Darwin Conwell MD, MS

Phil Hart MD

Somashekar Krishna, MBBS, MPH

Luis Lara, MD

Terence Williams, MD, PhD

Anne Noonan, MD

Tom Mace Ph.D.

Mary Dillhoff MD

Martha Belury Ph.D.

Lei Cao Ph.D.

Willa Hsueh MD

Joshua Blakeslee Ph.D.

Sue Knoblaugh DVM, Diplomate ACVP



## **Funding Sources:**

The James



Consortium for the Study of Chronic  
Pancreatitis, Diabetes, and Pancreatic Cancer

U01DK108327

